Rutanen E M, Stenman S, Blum W, Kärkkäinen T, Lehtovirta P, Stenman U H
Department I Of Obstetrics and Gynecology, Helsinki University Central Hospital, Finland.
J Clin Endocrinol Metab. 1993 Jul;77(1):199-204. doi: 10.1210/jcem.77.1.7686914.
Insulin is a major regulator of circulating insulin-like growth factor (IGF)-binding protein-1 (IGFBP-1), suppressing the hepatic production of IGFBP-1. Postmenopausal age, obesity, hypertension, and impaired glucose tolerance, which are known risk factors for endometrial cancer, are all associated with hyperinsulinemia and insulin resistance. In this study, we investigated the relationship among serum insulin, glucose, insulin-like growth factors (IGF-I and IGF-II), and IGFBP-, -2, and -3 in 32 nondiabetic postmenopausal women with endometrial cancer and in 18 healthy controls. The mean fasting levels of glucose and insulin were higher, whereas the mean basal IGF-I, IGF-II, and IGFBP-3 levels were lower in the endometrial cancer patients than in the healthy control subjects. The mean fasting IGFBP-1 and IGFBP-2 levels did not differ between the groups, and no correlation was found between fasting insulin and IGFBP-1 concentrations or between insulin and IGFBP-2 concentrations in either of the study groups. During an oral glucose tolerance test, the mean glucose levels at 1 and 3 h as well as the mean insulin level at 3 h were significantly higher in the endometrial cancer patients than in the controls, and the area under the glucose curve was larger in the first group. An oral glucose load resulted in a similar fall in serum IGFBP-1 levels in endometrial cancer patients and controls (51% and 55% at 3 h). When the cancer patients were divided into two subgroups according to the body mass index (kilograms per m2), the obese group had higher glucose and insulin indices than the nonobese group. No difference was found by the same measures in healthy controls. The fasting serum IGFBP-1 levels tended to be lower in the obese than in the normal weight subjects, but the difference did not reach statistical significance. In summary, these results provide preliminary evidence that the inverse relation between fasting insulin and IGFBP-1, well established in children and young adults, disappears in elderly women, although short term suppression by insulin still occurs. Further, our data indicate that in addition to carbohydrate metabolism, postmenopausal women with endometrial cancer have alterations in their circulating IGF system compared to controls.
胰岛素是循环胰岛素样生长因子(IGF)结合蛋白-1(IGFBP-1)的主要调节因子,可抑制肝脏中IGFBP-1的产生。绝经后年龄、肥胖、高血压和糖耐量受损是已知的子宫内膜癌危险因素,它们均与高胰岛素血症和胰岛素抵抗相关。在本研究中,我们调查了32例非糖尿病绝经后子宫内膜癌女性和18例健康对照者血清胰岛素、葡萄糖、胰岛素样生长因子(IGF-I和IGF-II)以及IGFBP-1、-2和-3之间的关系。与健康对照者相比,子宫内膜癌患者的空腹血糖和胰岛素平均水平较高,而基础IGF-I、IGF-II和IGFBP-3平均水平较低。两组间空腹IGFBP-1和IGFBP-2平均水平无差异,且在任何一个研究组中,空腹胰岛素与IGFBP-1浓度之间或胰岛素与IGFBP-2浓度之间均未发现相关性。在口服葡萄糖耐量试验期间,子宫内膜癌患者1小时和3小时的平均血糖水平以及3小时的平均胰岛素水平均显著高于对照组,且第一组的葡萄糖曲线下面积更大。口服葡萄糖负荷导致子宫内膜癌患者和对照组血清IGFBP-1水平出现相似程度的下降(3小时时分别为51%和55%)。根据体重指数(千克/平方米)将癌症患者分为两个亚组时,肥胖组的血糖和胰岛素指标高于非肥胖组。在健康对照者中,相同指标未发现差异。肥胖者的空腹血清IGFBP-1水平往往低于正常体重者,但差异未达到统计学意义。总之,这些结果提供了初步证据,表明在儿童和年轻人中已确立的空腹胰岛素与IGFBP-1之间的负相关关系在老年女性中消失,尽管胰岛素的短期抑制作用仍然存在。此外,我们的数据表明,与对照组相比,绝经后子宫内膜癌女性除碳水化合物代谢外,其循环IGF系统也存在改变。